Summary
SHARES in drugs giant AstraZeneca slumped to a 19-month low today as US regulators formally blocked the launch of its new blood- thinning treatment Exanta, writes Steve Hawkes.
AZ said it had received a letter from the US Food and Drug Administration detailing a decision not to approve the drug. It is now "considering how to proceed further".See the full content of this document
Extract
Az On the Sick List As Us Blocks Blood Drug
The shares fell 9p to 2156p, meaning A...
See the full content of this document
Sponsored links
